Previous 10 | Next 10 |
The following slide deck was published by Aurinia Pharmaceuticals Inc. in conjunction with their 2020 Q4 earnings call. For further details see: Aurinia Pharmaceuticals Inc. 2020 Q4 - Results - Earnings Call Presentation
Image source: The Motley Fool. Aurinia Pharmaceuticals Inc (NASDAQ: AUPH) Q4 2020 Earnings Call Feb 24, 2021 , 4:30 p.m. ET Operator Continue reading For further details see: Aurinia Pharmaceuticals Inc (AUPH) Q4 2020 Earnings Call Transc...
Aurinia Pharmaceuticals Inc. (AUPH) Q4 2020 Earnings Conference Call February 24, 2021 16:30 ET Company Participants Glenn Schulman - Senior Vice President, Investor Relations Peter Greenleaf - President and Chief Executive Officer Neil Solomons - Chief Medical Officer Max Colao - Chief Comme...
Aurinia Pharma (AUPH): Q4 GAAP EPS of -$0.05 beats by $0.15.Revenue of $50.03M (+166666.7% Y/Y) beats by $37.49M.Cash, cash equivalents, and investments of $423M at December 31, 2020.Shares +1.13%.Press Release For further details see: Aurinia Pharma EPS beats by $0.15, beats on revenue...
- LUPKYNIS TM is the first FDA-approved oral therapy for lupus nephritis (LN), a condition that causes irreversible kidney damage and increases the risk of kidney failure, cardiac events, and death - - Cash, cash equivalents, and investments of $423 million at December...
We propose a method for selling options that defies many myths around options selling. We analyzed options prices using statistical modelling and calculus to improve the "expected value" of trading versus conventional principles. Trades based on the criteria below are likely to wi...
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (the “Company”) today announced that members of the executive management team will participate in a fireside chat at the (virtual) SVB Leerink 10 th Annual Global Healthcare Conference on Thursday, February 25, 202...
On January 22, the FDA approved Voclosporin to treat Lupus Nephritis. A label was included with a personal dosage protocol, which implies that VC will be protected against generics until 2037. VC is expected to generate between $1B and $2B per year. Aurinia is going to be a pr...
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (the “Company”) today announced that it will release its fourth quarter and year end 2020 financial results on Wednesday, February 24, 2021, after the markets close. Aurinia’s management team will host a confere...
Hepion's leading candidate CRV431 may have the best anti-fibrotic effect among the numerous NASH candidates. CRV431's analogs have been widely studied in various clinical trials, and were proven to be well-tolerated. Hepion's management has extensive experience with cyclophilin in...
News, Short Squeeze, Breakout and More Instantly...
Aurinia Pharmaceuticals Inc Company Name:
AUPH Stock Symbol:
NASDAQ Market:
Aurinia Pharmaceuticals Inc Website:
Viridien ADR (CGGYD) is expected to report for Q2 2024 Civitas Resources Inc. (CIVI) is expected to report $2.9 for Q2 2024 Aptiv PLC (APTV) is expected to report $1.37 for Q2 2024 Ardelyx Inc. (ARDX) is expected to report $-0.1 for Q2 2024 Beazer Homes USA Inc. (BZH) is expected ...
Company achieved $57.2 million in total net revenue and $55.0 million in net product revenue for the second quarter of 2024, representing year-over-year growth of approximately 38% and 34% respectively Company generated approximately $15.8 million in free cash flow in the second quarter a...
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that it will release financial and operational results for the second quarter of 2024 on Thursday, August 1, 2024, before markets open. Aurinia’s management team will host a conference call/webcast at 8:30...